GENE ONLINE|News &
Opinion
Blog

2021-08-11| Special

Novel Triple Immunotherapy Combo Rekindles Hope for Pancreatic Cancer Patients

by Isha Kapoor
Share To
Pancreatic cancer is the third-leading cause of cancer-related deaths in the US. Despite mammoth advancements in improving chemotherapeutic regimens, metastatic pancreatic adenocarcinomas still pose a greater clinical challenge due to dismal prognosis. However, MIT researchers now develop a novel triple immunotherapy combo that could potentially shrink or even eliminate pancreatic tumors.

GO Prime with only $1.49 now

LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top